Evaluation of Self-Assembling Peptides (Curodont Protect) in Managing Post Bleaching Hypersensitivity

November 14, 2026 updated by: Ahmed Ezzat Mohamed Mohamed Kamel, Nahda University

Evaluation of Self-Assembling Peptides in Managing Post Bleaching Hypersensitivity

The goal of this clinical trial is to learn if using self assembling peptides reduce post operative bleaching hypersensitivity in middle aged patients (18-40).

Research will evaluate the efficacy of self-assembling peptide in reducing hypersensitivity after bleaching compared to Potassium Nitrate and Sodium Fluoride participants will all recive the same bleaching kit and protocol following the intruction provided by bleaching kit Will then be assorted into two groups which one will recive Potassium Nitrate and Sodium Fluoride and the other with recive self assembling peptide post bleaching Hypersensitivity will be evaluated immediately after the bleaching procedure , immediately after the application of the remineralizing/desensitizing agent , after 24 hours , and after one week

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

4 months to 9 months (Child)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age between 18 and 40 years.
  • All teeth that need bleaching are free from caries, filings or periodontal disease. - Low caries index.
  • Patients with VITA- color teeth shade A2 or darker.
  • Patients with cooperative behavior and medically free.

Exclusion Criteria:

  • Patients with severe intrinsic discoloration.
  • Patient with history of teeth hypersensitivity.
  • Taking analgesics/anti-inflammatory drugs at the time of the study, pregnancy, and smoking.
  • Any professional desensitizing therapy on the selected teeth during the last 6 months.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Power white After Whitening Mousse

Dispense a small amount and apply a thin layer of the After Whitening Mousse directly onto the surface of the teeth Allow the mousse to remain on the teeth for 10 to 15 minutes. The patient can often leave the dental practice with the mousse still applied

Active Comparator: Curodont protect

Apply the gel over the entire dentition or targeted teeth using a microbrush.

Leave the gel undisturbed for 1 to 2 minutes.

The patient can spit out any excess residue, but do not rinse immediately with water to allow the active ingredients to maintain contact with the enamel.

For sensitive teeth or professional cleanings/bleaching, apply 2 minutes before and after the procedure

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
The Effect of Self Assembling Peptides on treatment of post bleaching hypersensitivity using Visual Analog scale for assessment
Time Frame: from bleaching day up to 7 days
from bleaching day up to 7 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 18, 2026

Primary Completion (Estimated)

December 18, 2026

Study Completion (Estimated)

January 18, 2027

Study Registration Dates

First Submitted

November 4, 2026

First Submitted That Met QC Criteria

November 14, 2026

First Posted (Actual)

November 17, 2026

Study Record Updates

Last Update Posted (Actual)

November 17, 2026

Last Update Submitted That Met QC Criteria

November 14, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 00-A-1-26-1

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.